|
Post by agedhippie on Mar 3, 2020 13:47:14 GMT -5
It's a different API so the FDA would need to approve that. There is not a lot of point anyway because they are currently not using all the insulin they are buying from Amphastar. They are a lot more likely to burn down the Amphastar backlog for Brazil because it's already paid for and is the correct API. What is the status pf that Pfizer insulin? Does Mannkind really have 10 billion dollars worth of insulin locked away in a freezer somewhere? No. It was all discussed here - mnkd.proboards.com/thread/5712/mnkd-insulin-stockpile-street-value. The $10B number was the retail value of Afrezza that could be produced with the insulin if Mannkind exercised their option to buy the balance of the insulin from Pfizer. Up front Mannkind agreed to maintain the insulin Pfizer and were paid with $3M worth of the stock pile for that work. If Mannkind really owned $10B worth of insulin the balance sheet would look a whole lot healthier.
|
|
|
Post by brotherm1 on Mar 3, 2020 15:48:45 GMT -5
Good find Matt. Interesting that MC emphasized Brazil as a cash market where it would be sold to an affluent upper class and not part of the government formulary. Interesting to see how this reconciled over time. He did say part of the next shipment will ship in Q1 (later this month?), and the majority in Q2. Hopefully we will get a dollar amount associated with each shipment, close to the time of shipment, rather than waiting until the next earnings call. I’m so confused. I know MC said just last week the plan is to sell it high priced to the affluent. So is the pricing through CMED perhaps just meant for those with low income with national health care insurance?
|
|
|
Post by agedhippie on Mar 3, 2020 15:57:58 GMT -5
Good find Matt. Interesting that MC emphasized Brazil as a cash market where it would be sold to an affluent upper class and not part of the government formulary. Interesting to see how this reconciled over time. He did say part of the next shipment will ship in Q1 (later this month?), and the majority in Q2. Hopefully we will get a dollar amount associated with each shipment, close to the time of shipment, rather than waiting until the next earnings call. I’m so confused. I know MC said just last week the plan is to sell it high priced to the affluent. So is the pricing through CMED perhaps just meant for those with low income with national health care insurance? BIOMM have bought and paid for it, and now they can sell it however they want. This is not in Mike's control whatever he may say.
|
|
|
Post by ktim on Mar 4, 2020 20:17:12 GMT -5
It's a different API so the FDA would need to approve that. There is not a lot of point anyway because they are currently not using all the insulin they are buying from Amphastar. They are a lot more likely to burn down the Amphastar backlog for Brazil because it's already paid for and is the correct API. What is the status pf that Pfizer insulin? Does Mannkind really have 10 billion dollars worth of insulin locked away in a freezer somewhere? It's only worth as much as what they can sell it for. Seems as if there is no current market for it. Apparently no company that needs it has the regulatory approval to use it... Mannkind included.
|
|
|
Post by brotherm1 on Mar 4, 2020 20:55:28 GMT -5
I’m so confused. I know MC said just last week the plan is to sell it high priced to the affluent. So is the pricing through CMED perhaps just meant for those with low income with national health care insurance? BIOMM have bought and paid for it, and now they can sell it however they want. This is not in Mike's control whatever he may say. Well Mr. Castagna did just say at the Leerink presentation that the target in Brazil is the higher income that can pay cash. So I guess either he is grossly mistaken or the pricing listed herein by Matt is only for the lower income on the Brazilian government health care program.
|
|
|
Post by neil36 on Jun 1, 2020 10:31:23 GMT -5
Interesting that the BIOMM share price dipped down to $8.85 in late March but is now at a record high above $20 a share, including a 25%+ pop this morning.
|
|
|
Post by jlaw277 on Jun 1, 2020 16:32:39 GMT -5
|
|
|
Post by agedhippie on Jun 1, 2020 16:35:46 GMT -5
Interesting that the BIOMM share price dipped down to $8.85 in late March but is now at a record high above $20 a share, including a 25%+ pop this morning. It's what happens when you get a large buy in a thinly traded stock. They increased the share count to allow a buy in by the local government investment bank so my guess is that was it hitting. The volume was 438k vs. an average of 29k. It will be interesting to see what happens to the volume, but my bet would be that it rapidly reverts.
|
|
|
Post by ktim on Oct 27, 2020 19:25:41 GMT -5
I haven't been watching MNKD very closely this year. Was there any positive development with Brazil? Any shipments beyond first? Any indication of Rx numbers?
|
|
|
Post by mytakeonit on Oct 28, 2020 1:22:10 GMT -5
I believe that the second container was shipped ... but, we have to wait for the conference call to see what is real.
But, that's mytakeonit
|
|
|
Post by mnkdfann on Oct 28, 2020 2:08:32 GMT -5
I haven't been watching MNKD very closely this year. Was there any positive development with Brazil? Any shipments beyond first? Any indication of Rx numbers? August: seekingalpha.com/article/4364989-mannkind-corporations-mnkd-ceo-michael-castagna-on-q2-2020-results-earnings-call-transcript?part=single"The second quarter included $0.2 million of sales to a Brazilian marketing partner, Biomm." September: seekingalpha.com/article/4374415-mannkind-corporation-mnkd-ceo-michael-castagna-presents-cantor-2020-global-virtual-healthcare?part=singleAnalyst: Anything you can talk about international side to Afrezza? Michael Castagna Yeah. It’s a tough one right for everybody. Unfortunately, our first two markets outside the U.S. were Brazil and India. And both have been majorly hit by COVID. I mean, India is just in deep trouble right now. And one of things, I'm internally talking with our team saying, how do we go back to the regulatory authorities, there diabetes out of control with COVID is that much more of an urgent need? Can we go and help faster? Who knows what the regulatory authorities want? For me, 81 million people with an average age everyone see is not good for society, can we bring those so everyone see them or choose. That'll be important for India. Brazil now launched, it's mainly a cash trade market down there right now. And, they've been growing sales each month since they launched. But, obviously, it's tough environment for them to get out. But I think they're building up nicely, the feedback from doctors is positive, the patients are positive. Not everyone that's on the drug -- that’s very developed down there. So I feel like the experience has been great. We just need to get the volume up. And I think I hope it's just a little bit of a headwind against them. But they're going to be doing some more things down there as they get ready for next year and the rest of this year. So I don't have any big expectations for international in the next few months. But I think that business will continue to build as we go into next year and beyond.
|
|